Adverse health outcomes for prostate cancer patients treated with radiotherapy combined with androgen-deprivation therapy: A population-based, controlled study, from Norway
Background and purpose : The aim of this controlled cross-sectional, and population-based study was to evaluate adverse health outcomes (AHOs) 3 years after curative radiotherapy (RT) + androgen deprivation therapy (ADT). We also assessed Global Health/Quality of Life (QoL). Patients/material and m...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Medical Journals Sweden
2025-08-01
|
| Series: | Acta Oncologica |
| Subjects: | |
| Online Access: | https://medicaljournalssweden.se/actaoncologica/article/view/42825 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849224588330795008 |
|---|---|
| author | Mona Nilsson Anne Holck Storaas Tom Børge Johannesen Ylva Maria Gjelsvik Kirsti Aas Sophie Dorthea Fosså Tor Åge Myklebust |
| author_facet | Mona Nilsson Anne Holck Storaas Tom Børge Johannesen Ylva Maria Gjelsvik Kirsti Aas Sophie Dorthea Fosså Tor Åge Myklebust |
| author_sort | Mona Nilsson |
| collection | DOAJ |
| description | Background and purpose : The aim of this controlled cross-sectional, and population-based study was to evaluate adverse health outcomes (AHOs) 3 years after curative radiotherapy (RT) + androgen deprivation therapy (ADT). We also assessed Global Health/Quality of Life (QoL).
Patients/material and methods: The Cancer Registry of Norway (CRN) provided data on prostate cancer (PCa) patients diagnosed in 2017–2019. All had been treated with RT+ ADT. All had completed EPIC-26 and EORTC QLQ-C30 about 3 years after RT start (n = 663). ADT duration was stratified: Short (< 9 months), intermediate (9–18 months) and long ADT (18–24 months). A group of controls were established from the general population (n = 1,817). Outcome measures were the urinary irritative/obstructive domain summary score (DSS), the bowel and sexual DSSs (EPIC-26) and QoL (EORTC QLQ-C30).
Results: Compared to controls, patients had clinically important lower bowel, and sexual mean scores. Urinary irritative/obstructive DSS levels were similar. Overall, 43% (PCa patients) and 20% (controls) reported major sexual problems. In patients aged < 75 years, longer than short ADT duration significantly decreased sexual DSS. QoL was relatively unaffected. Low response rates, selection bias and a lack of pre-treatment data represent the studys´ limitations.
Conclusion and Interpretation: Three years post-RT+ADT, PCa patients describe clinically important lower EPIC-26 bowel and sexual DSS compared to controls. Sexual domain levels decreased with increasing ADT duration, particularly in patients < 75 years. Our observations indicate worse AHOs than previously reported and should be considered during pre-treatment counselling of PCa patients.
|
| format | Article |
| id | doaj-art-efbe9fa8392d4f18901ae4ee54d49a41 |
| institution | Kabale University |
| issn | 1651-226X |
| language | English |
| publishDate | 2025-08-01 |
| publisher | Medical Journals Sweden |
| record_format | Article |
| series | Acta Oncologica |
| spelling | doaj-art-efbe9fa8392d4f18901ae4ee54d49a412025-08-25T07:54:42ZengMedical Journals SwedenActa Oncologica1651-226X2025-08-016410.2340/1651-226X.2025.42825Adverse health outcomes for prostate cancer patients treated with radiotherapy combined with androgen-deprivation therapy: A population-based, controlled study, from NorwayMona Nilsson0Anne Holck Storaas1https://orcid.org/0000-0002-9376-9163Tom Børge Johannesen2Ylva Maria Gjelsvik3https://orcid.org/0000-0001-5027-9482Kirsti Aas4Sophie Dorthea Fosså5https://orcid.org/0000-0002-3729-2217Tor Åge Myklebust6https://orcid.org/0000-0003-4645-1635Cancer Registry of Norway, Norwegian Institute of Public Health, Oslo, Norway; Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, NorwayCancer Registry of Norway, Norwegian Institute of Public Health, Oslo, Norway; Department of Oncology, Oslo University Hospital, Oslo, NorwayCancer Registry of Norway, Norwegian Institute of Public Health, Oslo, NorwayCancer Registry of Norway, Norwegian Institute of Public Health, Oslo, NorwayInstitute of Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway; Department of Urology, Akershus University Hospital, Lørenskog, NorwayInstitute of Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway; Department of Oncology, Oslo University Hospital, Oslo, NorwayCancer Registry of Norway, Norwegian Institute of Public Health, Oslo, Norway; Department of Research and Innovation, Møre and Romsdal Hospital Trust, Ålesund, Norway Background and purpose : The aim of this controlled cross-sectional, and population-based study was to evaluate adverse health outcomes (AHOs) 3 years after curative radiotherapy (RT) + androgen deprivation therapy (ADT). We also assessed Global Health/Quality of Life (QoL). Patients/material and methods: The Cancer Registry of Norway (CRN) provided data on prostate cancer (PCa) patients diagnosed in 2017–2019. All had been treated with RT+ ADT. All had completed EPIC-26 and EORTC QLQ-C30 about 3 years after RT start (n = 663). ADT duration was stratified: Short (< 9 months), intermediate (9–18 months) and long ADT (18–24 months). A group of controls were established from the general population (n = 1,817). Outcome measures were the urinary irritative/obstructive domain summary score (DSS), the bowel and sexual DSSs (EPIC-26) and QoL (EORTC QLQ-C30). Results: Compared to controls, patients had clinically important lower bowel, and sexual mean scores. Urinary irritative/obstructive DSS levels were similar. Overall, 43% (PCa patients) and 20% (controls) reported major sexual problems. In patients aged < 75 years, longer than short ADT duration significantly decreased sexual DSS. QoL was relatively unaffected. Low response rates, selection bias and a lack of pre-treatment data represent the studys´ limitations. Conclusion and Interpretation: Three years post-RT+ADT, PCa patients describe clinically important lower EPIC-26 bowel and sexual DSS compared to controls. Sexual domain levels decreased with increasing ADT duration, particularly in patients < 75 years. Our observations indicate worse AHOs than previously reported and should be considered during pre-treatment counselling of PCa patients. https://medicaljournalssweden.se/actaoncologica/article/view/42825Prostate cancerRadiotherapyAndrogen deprivation therapyEPIC-26 domain summary scoresQuality of lifeLate effects |
| spellingShingle | Mona Nilsson Anne Holck Storaas Tom Børge Johannesen Ylva Maria Gjelsvik Kirsti Aas Sophie Dorthea Fosså Tor Åge Myklebust Adverse health outcomes for prostate cancer patients treated with radiotherapy combined with androgen-deprivation therapy: A population-based, controlled study, from Norway Acta Oncologica Prostate cancer Radiotherapy Androgen deprivation therapy EPIC-26 domain summary scores Quality of life Late effects |
| title | Adverse health outcomes for prostate cancer patients treated with radiotherapy combined with androgen-deprivation therapy: A population-based, controlled study, from Norway |
| title_full | Adverse health outcomes for prostate cancer patients treated with radiotherapy combined with androgen-deprivation therapy: A population-based, controlled study, from Norway |
| title_fullStr | Adverse health outcomes for prostate cancer patients treated with radiotherapy combined with androgen-deprivation therapy: A population-based, controlled study, from Norway |
| title_full_unstemmed | Adverse health outcomes for prostate cancer patients treated with radiotherapy combined with androgen-deprivation therapy: A population-based, controlled study, from Norway |
| title_short | Adverse health outcomes for prostate cancer patients treated with radiotherapy combined with androgen-deprivation therapy: A population-based, controlled study, from Norway |
| title_sort | adverse health outcomes for prostate cancer patients treated with radiotherapy combined with androgen deprivation therapy a population based controlled study from norway |
| topic | Prostate cancer Radiotherapy Androgen deprivation therapy EPIC-26 domain summary scores Quality of life Late effects |
| url | https://medicaljournalssweden.se/actaoncologica/article/view/42825 |
| work_keys_str_mv | AT monanilsson adversehealthoutcomesforprostatecancerpatientstreatedwithradiotherapycombinedwithandrogendeprivationtherapyapopulationbasedcontrolledstudyfromnorway AT anneholckstoraas adversehealthoutcomesforprostatecancerpatientstreatedwithradiotherapycombinedwithandrogendeprivationtherapyapopulationbasedcontrolledstudyfromnorway AT tombørgejohannesen adversehealthoutcomesforprostatecancerpatientstreatedwithradiotherapycombinedwithandrogendeprivationtherapyapopulationbasedcontrolledstudyfromnorway AT ylvamariagjelsvik adversehealthoutcomesforprostatecancerpatientstreatedwithradiotherapycombinedwithandrogendeprivationtherapyapopulationbasedcontrolledstudyfromnorway AT kirstiaas adversehealthoutcomesforprostatecancerpatientstreatedwithradiotherapycombinedwithandrogendeprivationtherapyapopulationbasedcontrolledstudyfromnorway AT sophiedortheafossa adversehealthoutcomesforprostatecancerpatientstreatedwithradiotherapycombinedwithandrogendeprivationtherapyapopulationbasedcontrolledstudyfromnorway AT toragemyklebust adversehealthoutcomesforprostatecancerpatientstreatedwithradiotherapycombinedwithandrogendeprivationtherapyapopulationbasedcontrolledstudyfromnorway |